Literature DB >> 8888126

Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation.

M Peet1, J D Laugharne, J Mellor, C N Ramchand.   

Abstract

There is now convincing evidence that membrane phospholipid metabolism is abnormal in schizophrenic patients. Our own studies, consistent with those of other research groups, have shown marked depletion of essential fatty acids, particularly arachidonic acid and docosahexanoic acid, in red blood cell membranes from schizophrenic patients relative to healthy control subjects. We also present preliminary evidence that similar abnormalities are present in first degree relatives of schizophrenic patients. Furthermore, it appears that changes in diet, which modify membrane levels of fatty acids, can have significant effects upon symptoms of schizophrenia and tardive dyskinesia (TD). Thus, we have found that schizophrenic patients who eat more (n-3) fatty acids in their normal diet have less severe symptoms. In a pilot study of (n-3) fatty acid supplementation we observed significant improvement in both schizophrenic symptoms and tardive dyskinesia over a 6 week period.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8888126     DOI: 10.1016/s0952-3278(96)90148-9

Source DB:  PubMed          Journal:  Prostaglandins Leukot Essent Fatty Acids        ISSN: 0952-3278            Impact factor:   4.006


  17 in total

1.  Increased CNS levels of apolipoprotein D in schizophrenic and bipolar subjects: implications for the pathophysiology of psychiatric disorders.

Authors:  E A Thomas; B Dean; G Pavey; J G Sutcliffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-27       Impact factor: 11.205

Review 2.  The influences of diet and exercise on mental health through hormesis.

Authors:  Fernando Gomez-Pinilla
Journal:  Ageing Res Rev       Date:  2007-05-05       Impact factor: 10.895

3.  Differential effects of modulation of docosahexaenoic acid content during development in specific regions of rat brain.

Authors:  Beth Levant; Marlies K Ozias; Karra A Jones; Susan E Carlson
Journal:  Lipids       Date:  2006-05       Impact factor: 1.880

Review 4.  Antioxidants, redox signaling, and pathophysiology in schizophrenia: an integrative view.

Authors:  Jeffrey K Yao; Matcheri S Keshavan
Journal:  Antioxid Redox Signal       Date:  2011-04-21       Impact factor: 8.401

Review 5.  Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications.

Authors:  J K Yao; R D Reddy; D P van Kammen
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 6.  Polyunsaturated fatty acids and cerebral function: focus on monoaminergic neurotransmission.

Authors:  S Chalon; S Vancassel; L Zimmer; D Guilloteau; G Durand
Journal:  Lipids       Date:  2001-09       Impact factor: 1.880

Review 7.  The neurobiology of apolipoproteins in psychiatric disorders.

Authors:  J Gregor Sutcliffe; Elizabeth A Thomas
Journal:  Mol Neurobiol       Date:  2002 Oct-Dec       Impact factor: 5.590

8.  Levels of Red Blood Cell Fatty Acids in Patients With Psychosis, Their Unaffected Siblings, and Healthy Controls.

Authors:  Suzanne Medema; Roel J T Mocking; Maarten W J Koeter; Frédéric M Vaz; Carin Meijer; Lieuwe de Haan; Nico J M van Beveren; René Kahn; Lieuwe de Haan; Jim van Os; Durk Wiersma; Richard Bruggeman; Wiepke Cahn; Carin Meijer; Inez Myin-Germeys
Journal:  Schizophr Bull       Date:  2015-09-18       Impact factor: 9.306

Review 9.  Brain foods: the effects of nutrients on brain function.

Authors:  Fernando Gómez-Pinilla
Journal:  Nat Rev Neurosci       Date:  2008-07       Impact factor: 34.870

10.  Superoxide dismutase and cytokines in chronic patients with schizophrenia: association with psychopathology and response to antipsychotics.

Authors:  Xiang Yang Zhang; Dong Feng Zhou; Ling Yan Qi; Song Chen; Lian Yuan Cao; Da Chun Chen; Mei Hong Xiu; Fan Wang; Gui Ying Wu; Lin Lu; Therese A Kosten; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2009-01-13       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.